1H-MRS metabonomic analysis of plasma samples of esophageal cancer patients based on different pattern recognition.
- Author:
Hasim AYSHAMGUL
1
;
Mamtimin BATUR
;
Sheyhidin ILYAR
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Blood Chemical Analysis; China; ethnology; Discriminant Analysis; Esophageal Neoplasms; blood; Female; Humans; Least-Squares Analysis; Magnetic Resonance Spectroscopy; Male; Metabolomics; Middle Aged; Plasma; metabolism; Principal Component Analysis
- From: Chinese Journal of Oncology 2010;32(9):681-684
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the metabonomic (1)H-MRS of plasma samples from patients with esophageal cancer and healthy controls applying different pattern recognition methods, and to explore the potential of application of (1)H-MR-based metabonomics in clinical research.
METHODS(1)H-MR was performed on plasma samples from 109 EC patients and 50 health controls to analyze the metabonomic variation between EC patients and healthy subjects and the corresponding (1)H-MRS were recorded on Varian Unity ANOVA 600 MHz to perform principal components analysis (PCA), partial least squares discriminant analysis (PLS-DA), orthogonal partial least squares discriminant analysis (OPLS-DA), respectively.
RESULTSOPLS-DA analysis could correctly separate almost all the plasma samples from EC patients and health controls, better than both the PCA and PLS-DA. The plasma levels of leucine, alanine, isoleucine, valine, glycoprotein, lactate, acetone, acetate, choline, isobutyrate, unsaturated lipid, VLDL, LDL, 1-methylhistidine were significantly decreased in EC patients (r total > 0.27, P < 0.05), while that of dimethylamine, α-glucose, β-glucose, citric acid increased in the EC patients (r total < -0.27, P < 0.05).
CONCLUSIONSThe analysis of metabonomic (1)H-MRS of plasma samples by OPLS-DA method can eliminate the influence of non-experimental factors and decrease the heterogeneity of samples. It is useful and of great potential for application in clinical diagnosis and research of esophageal cancer.